You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 23, 2025

Patent: 10,085,955


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,085,955
Title:Methods and compositions for treatment of demyelinating diseases
Abstract: Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.
Inventor(s): Blitzer; Jeremy (San Francisco, CA), McKearn; John (Saint Louis, MO)
Assignee: Pathologica LLC (San Francisco, CA)
Application Number:14/759,599
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,085,955

Introduction

United States Patent 10,085,955, like any other patent, is a complex document that requires a thorough analysis to understand its claims, validity, and position within the broader patent landscape. This analysis will delve into the key aspects of the patent, including its claims, the legal framework governing its validity, and the tools and strategies for evaluating its strength and relevance.

Understanding the Patent Claims

To analyze the claims of a patent like 10,085,955, it is crucial to break down each claim and assess its scope and specificity.

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[5].

Claim Analysis

For example, if the patent in question involves AI-related inventions, the claims must integrate a judicial exception into a practical application to be considered patent-eligible. This involves assessing whether the claimed invention offers a concrete technological improvement and whether it provides meaningful limits on the exception, transforming the claim into patent-eligible subject matter[2].

Legal Framework and Patent Eligibility

The patent eligibility of claims is governed by several key legal principles and guidelines.

America Invents Act (AIA)

The AIA, enacted in 2011, significantly altered the U.S. patent system by introducing new types of administrative challenges to patent validity, such as Inter Partes Review (IPR) and Post-Grant Review (PGR). These processes, handled by the Patent Trial and Appeal Board (PTAB), provide a faster and less expensive alternative to judicial proceedings for challenging patent validity[5].

Subject Matter Eligibility

The USPTO has issued guidelines for determining whether a patent application seeks to claim ineligible subject matter. The Alice/Mayo test is a two-step process that determines if the patent claims are directed to ineligible subject matter (such as laws of nature, natural phenomena, or abstract ideas) and if they contain an "inventive concept" that transforms the nature of the claim into a patent-eligible application[5].

Oversight and Independence of PTAB Judges

The PTAB, responsible for reviewing patent applications and hearing challenges to patent validity, operates under the oversight of the USPTO director and PTAB management. However, there have been concerns about the independence of PTAB judges.

Management Oversight

A significant majority of PTAB judges have reported that oversight by USPTO directors and PTAB management has affected their independence. This oversight can influence decisions on whether to institute a trial based on discretionary factors, although it rarely affects the merits of the case itself[1].

Advanced Patent Searching Techniques

To fully evaluate the strength and relevance of a patent, advanced patent searching techniques are essential.

Patent Family Searching

Understanding the scope and coverage of related patents within a family is crucial. This involves analyzing the initial set of claims and any amendments or narrowing of claims during the prosecution process. Tools like the Global Dossier and Common Citation Document (CCD) facilitate this by providing access to file histories and citation data from participating IP offices[3][4].

Public Search Facilities

The USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs) offer resources and training in patent search techniques, helping to identify relevant prior art and assess the novelty and nonobviousness of the claimed invention[4].

Recent USPTO Guidance on AI Patents

For patents involving AI-related inventions, recent USPTO guidance updates are particularly relevant.

AI-Assisted Inventions

The 2024 USPTO guidance update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring there is significant human contribution and that the invention integrates a judicial exception into a practical application[2].

Practical Applications

Highlighting the real-world applications of the claimed method or system is crucial for demonstrating patent eligibility. For example, specifying the use of separated audio components in a speech recognition system to enhance the accuracy of voice commands in hands-free environments can transform an abstract idea into a patent-eligible invention[2].

Case Law and Judicial Precedents

The interpretation of patent claims and their eligibility is often shaped by recent case law.

Alice/Mayo Test

The Alice/Mayo test, as mentioned earlier, is a critical framework for determining patent eligibility. Claims must contain elements sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself[5].

Key Takeaways

  • Claim Specificity: Patent claims must be specific and integrate judicial exceptions into practical applications to be considered patent-eligible.
  • Oversight and Independence: PTAB judges face oversight from USPTO directors and management, which can influence their decisions, particularly on discretionary factors.
  • Advanced Searching: Utilizing tools like Global Dossier and CCD is essential for comprehensive patent family searching and evaluating prior art.
  • AI Patents: Recent USPTO guidance emphasizes the importance of significant human contribution and practical applications in AI-assisted inventions.
  • Legal Framework: The AIA and Alice/Mayo test are pivotal in determining patent validity and eligibility.

FAQs

Q: What is the role of the PTAB in the U.S. patent system? A: The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, providing a faster and less expensive alternative to judicial proceedings[5].

Q: How does the USPTO determine patent eligibility for AI-related inventions? A: The USPTO determines patent eligibility by assessing whether the claimed invention integrates a judicial exception into a practical application and whether it provides meaningful limits on the exception, ensuring significant human contribution[2].

Q: What is the impact of management oversight on PTAB judges? A: Management oversight can affect the independence of PTAB judges, particularly in decisions on whether to institute a trial based on discretionary factors, although it rarely affects the merits of the case itself[1].

Q: What tools are available for advanced patent searching? A: Tools such as the Global Dossier, Common Citation Document (CCD), and resources from the USPTO Public Search Facility and PTRCs are available for comprehensive patent searching[3][4].

Q: How does recent case law influence patent eligibility? A: Recent case law, particularly the Alice/Mayo test, plays a crucial role in determining whether patent claims contain an "inventive concept" that transforms the nature of the claim into a patent-eligible application[5].

Sources

  1. GAO Report: "Patent Trial and Appeal Board: Preliminary Observations on Oversight Practices and Policies"[1].
  2. Mintz Insights: "Understanding the 2024 USPTO Guidance Update on AI Patent"[2].
  3. CAS Insights: "Advanced patent searching techniques - CAS.org"[3].
  4. USPTO: "Search for patents - USPTO"[4].
  5. Congressional Research Service: "The Patent Trial and Appeal Board and Inter Partes Review"[5].

More… ↓

⤷  Try for Free

Details for Patent 10,085,955

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 July 23, 1993 10,085,955 2033-01-08
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 May 17, 1996 10,085,955 2033-01-08
Biogen Inc. AVONEX interferon beta-1a Injection 103628 May 28, 2003 10,085,955 2033-01-08
Biogen Inc. AVONEX interferon beta-1a Injection 103628 February 27, 2012 10,085,955 2033-01-08
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.